BioLife Solutions Inc.

Bothell, WA, United States

BioLife Solutions Inc.

Bothell, WA, United States
SEARCH FILTERS
Time filter
Source Type

BOTHELL, Wash., May 4, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the Company's first...


BOTHELL, Wash., Aug. 3, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the Company's second...


BOTHELL, Wash., July 31, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that it...


News Article | August 10, 2017
Site: www.prnewswire.com

BOTHELL, Wash., Aug. 10, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today...


BOTHELL, Wash., July 13, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading supplier of pre-formulated, clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), today announced that Kolon Life Science, TissueGene's exclusive li...


BOTHELL, Wash., June 14, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain...


News Article | May 11, 2017
Site: www.prnewswire.com

BOTHELL, Wash., May 11, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today re...


The present invention is directed to systems and proteogenomic methods for predicting the success of the transplant of a cell, tissue, or organ by providing a means to determine the quality of the cell, tissue, or organ to be transplanted. In one embodiment, the present invention uses samples from the preservation solution to obtain phenomic fingerprints correlated with transplant pre-operative and post-operative data as a pre-operative tissue diagnostic and procedural success predictive indicator.


Patent
BioLife Solutions Inc. | Date: 2014-02-02

The present invention relates to materials and methods for hypothermic collection of whole blood, and components thereof, which can extend the holding time of blood beyond the current usable limit. Additionally, blood can be drawn directly into a hypothermic preservation solution without the addition of standard anticoagulants. This is enabled by providing sustained cellular viability under hypothermic conditions using a nutrient matrix devoid of animal proteins and containing energy substrates, free-radical scavengers, and impermeants that is ionically balanced for storage of biologic materials at low temperatures to prevent cellular stress-induced apoptosis.


BOTHELL, Wash., March 2, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the...

Loading BioLife Solutions Inc. collaborators
Loading BioLife Solutions Inc. collaborators